| Revenue from operations fell 39.46% YoY to Rs 739.1 crore in the quarter ended 31 March 2026.
Profit before tax (PBT) declined sharply by 71.51% to Rs 144.1 crore in Q4 FY26 from Rs 505.9 crore recorded in Q4 FY25.
On the segmental front, revenue from the pharmaceuticals business stood at Rs 716.5 crore, down 40.58% year-on-year. Meanwhile, revenue from the agro chemicals segment increased 50.66% YoY to Rs 716.5 crore in Q4 FY26.
For the full financial year FY26, Natco Pharma reported a 24.76% decline in consolidated net profit to Rs 1,418.5 crore. Revenue from operations decreased 7.92% year-on-year to Rs 4,078.3 crore in FY26.
NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.
|